2021 Annual Business Report

European Manufacturing Network

Our manufacturing base in Europe provides a long-term and sustainable industrial network to supply commercial and clinical products. We operate three manufacturing sites augmented by contract manufacturing partners.

European Manufacturing Network

The strength of an integrated business model

Valneva has a robust manufacturing network in place with facilities across Europe to meet its clinical and commercial needs.

  • The Company operates three manufacturing sites – in Livingston, Scotland; Solna, Sweden; and Vienna, Austria – which are licensed by several regulatory authorities.
  • Valneva’s viral manufacturing center in Livingston is currently being expanded in order to produce its COVID-19 vaccine candidate, VLA2001.
  • Valneva is also expanding its manufacturing site in Solna, establishing a new, dedicated facility for filling, labelling and packaging.
  • Valneva’s manufacturing network has been operating and producing licensed vaccines for more than 10 years.
  • The Company augments its production through contract manufacturing partners, such as IDT Biologika for VLA2001.